4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near term could have a huge impact on the stocks.
A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near term could have a huge impact on the stocks.
Axsome Therapeutics entered the market on Thursday morning at a price below the previously announced expected pricing range.
Celladon and Eiger BioPharmaceuticals have announced that they have entered into a definitive merger agreement.
We have word from UnitedHealth Group in an earnings warning that could be a serious blow to at least part of ACA/Obamacare.
Turing Pharmaceuticals CEO Martin Shkreli took a major stake in this small biopharma company KaloBios Pharmaceuticals over the course of this week.
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Ocera Therapeutics broke out in Tuesday's trading session following positive results from a clinical study.
Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
Clovis Oncology was leading the bears in Monday’s trading session on news that its lung cancer drug may be delayed.
Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early clinical stages.
Being added to the S&P 500 Index comes with a certain amount of prestige. It can also come with a big financial boost in some cases. When it comes to what that means for Illumina Inc.…
The biotech companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week.
Alcobra has announced the pricing of its underwritten secondary offering for more than 6 million shares.
Hutchison China MediTech has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
In a fresh report, Janney Capital Markets has said that bad news for Horizon Pharma is creating a buying opportunity in DepoMed.